SCHEMBL130617

SCHEMBL130617

[C]1=CC2C=CC=CC2=CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4686582 0.67
SCHEMBL5534615 0.67
SCHEMBL1256184 0.65
Hydrochloric Acid SCHEMBL9670232 0.64
SCHEMBL11214806 0.64
SCHEMBL359416 0.62
SCHEMBL3818681 0.62
SCHEMBL3444889 0.62
SCHEMBL381652 0.62
SCHEMBL17749950 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017186855-A1 UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE FORSCHUNGSVERBUND BERLIN E.V. (DE) 2017-11-02 WO claimed
CN-117642185-A Improved CD30 targeting antibody drug conjugates and uses thereof 路德维希-马克西米利安慕尼黑大学 2024-03-01 CN disclosed
WO-2024010015-A1 PYRIMIDINE DERIVATIVES あすか製薬株式会社 2024-01-11 WO disclosed
EP-3372589-B1 PYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2021-10-20 EP disclosed
US-10710967-B2 Pyrimidine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2020-07-14 US disclosed
US-20200071280-A1 PYRIMIDINE DERIVATIVE ASKA PHARMACEUTICAL CO., LTD. (JP) 2020-03-05 US disclosed
EP-3372589-A1 PYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2018-09-12 EP disclosed
WO-2017186855-A1 UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE FORSCHUNGSVERBUND BERLIN E.V. (DE) 2017-11-02 WO disclosed
US-20160257651-A1 NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY JUNTENDO EDUCATIONAL FOUNDATION (JP) 2016-09-08 US disclosed
EP-2987787-A1 NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY Juntendo Educational Foundation (JP) 2016-02-24 EP disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed
EP-0602376-B1 N,N-Disubstituted sulfonamides and radiation-sensitive composition produced therewith HOECHST AG (DE) 1997-04-23 EP disclosed
US-5612169-A USED IN MANUFACTURE OF OFFSET PRINTING PLATES AND PHOTORESISTS HOECHST AKTIENGESELLSCHAFT (DE) 1997-03-18 US disclosed
EP-0602377-B1 Polymers containing N,N-disubstituted sulfonamide side groups and their use in radiation-sensitive compositions HOECHST AG (DE) 1996-10-09 EP disclosed
US-5529886-A PHOTOSENSITIVE MIXTURE OF A COMPOUND WHICH ON EXPOSURE TO ACTINIC RADIATION FORMS ACID, AND AN ACID-CLEAVABLE ACRYLATE HOMO OR COPOLYMER HOECHST AKTIENGESELLSCHAFT (DE) 1996-06-25 US disclosed
US-5442087-A Preparing offset printing plates and photoresists HOECHST AKTIENGESELLSCHAFT (DE) 1995-08-15 US disclosed
EP-0602376-A1 N,N-Disbustituted sulfonamides and radiation-sensitive composition produced therewith HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-22 EP disclosed
EP-0602377-A1 Polymers containing N,N-disubstituted sulfonamide side groups and their use in radiation-sensitive compositions HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-22 EP disclosed